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Introduction
Anakinra is a recombinant, non-glycosylated form of the
human IL-1 receptor antagonist, which recently was
approved in US for neonatal onset multisystem inflam-
matory disease (NOMID), the most severe form of the
Cryopyrin-Associated Periodic Syndromes (CAPS). This
autoinflammatory disease can be effectively controlled
by daily subcutaneous administrations of Kineret[1-3].
The recommended initial dose is 1-2 mg/kg/day and the
average maintenance dose is 3-4 mg/kg/day.
Objectives
To evaluate if anti-drug antibodies (ADAs) correlate
with outcome measures in severe CAPS patients on
Kineret.
Methods
Forty patients treated up to 5 years and with pre- and
post-baseline antibody data were included in long-term
evaluations of ADA impact on pharmacokinetic para-
meters (dose-normalized maximum serum concentra-
tion, Cmax, and area under the serum concentration
time curve, AUC0-24h), body-weight adjusted Kineret
dose, change in Diary Symptom Sum Score (DSSS, i.e.
sum score for fever, rash, joint pain, vomiting, and head-
ache), change in C-reactive protein (hs-CRP) levels, and
treatment emergent adverse events (AEs).
ADAs were assessed with a bridging format immu-
noassay applying Meso Scale Discovery Electrochemilu-
minescence (MSD-ECL) technology. Data from pre-dose
samples were used to calculate a cut point with a false
positive rate of 5%. Screened positive samples were
further confirmed by competitive inhibition.
For statistical analyses the patients were classified
based on the presence of ADAs.
Results
No patient had ADAs at baseline, while 82.5% of the
patients exhibited ADAs at least once during the study.
The exposure to Kineret was 73.8 patient-years when
ADAs were not present and 82.2 patient-years when
ADAs were present. The daily dose of Kineret at Month
36 [mean(SD)] for patients with ADAs not present was
2.7(0.6) mg/kg and for patients with ADAs present 3.1
(0.8) mg/kg. The following estimates for the ADA nega-
tive and ADA positive patient groups, respectively, were
obtained: dose normalized Cmax 1164(554) vs. 941(406)
ng/mL/mg/kg, dose normalized AUC 15.0(6.5) vs. 12.6
(5.8) μg·h/mL/mg/kg, change in hs-CRP from baseline
-53(41) vs. -60(34) mg/L, and change in DSSS from
baseline -2.5(1.8) vs. -2.7(1.4). DSSS decreased signifi-
cantly within a few days in all patients with sustained
effect and continuous suppression of inflammatory
serum markers. No trend by antibody status was seen
for the rate of AEs related to allergies, injection site
reactions or symptoms of CAPS.
Conclusion
The majority of the severe CAPS patients on Kineret
developed transient or persistent ADAs. No correlation
was seen between the presence of ADAs and Kineret
dose, PK parameters, efficacy outcomes or AEs.
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